ストックスクリーナーアプリを入手
35.02
1.46%
-0.52
アフターアワーズ：
35.02
前日終値:
$35.54
開ける：
$35.82
24時間の取引高:
1.05M
Relative Volume:
1.55
時価総額：
$2.93B
収益：
$13.17M
当期純損益:
$-199.06M
株価収益率:
-12.78
EPS:
-2.74
ネットキャッシュフロー:
$-156.53M
1週間 パフォーマンス:
-8.52%
1か月 パフォーマンス:
+10.86%
6か月 パフォーマンス:
-22.18%
1年 パフォーマンス:
-17.58%
1日の値動き範囲:
$34.97
$36.40
1週間の範囲:
$34.47
$38.47
52週間の値動き範囲:
$26.74
$46.00
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
名前
Xenon Pharmaceuticals Inc
セクター
電話
(604) 484-3300
住所
200 - 3650 GILMORE WAY, BURNABY
XENE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
35.02 | 2.93B | 13.17M | -199.06M | -156.53M | -2.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-07 | 開始されました | Chardan Capital Markets | Buy |
| 2025-02-11 | 開始されました | Deutsche Bank | Buy |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-10-01 | 開始されました | H.C. Wainwright | Buy |
| 2024-01-04 | 開始されました | Citigroup | Buy |
| 2023-12-08 | 開始されました | Robert W. Baird | Outperform |
| 2023-10-24 | 再開されました | Cantor Fitzgerald | Overweight |
| 2023-04-25 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-12-14 | 開始されました | Goldman | Buy |
| 2022-12-12 | 開始されました | Cowen | Outperform |
| 2022-11-28 | 開始されました | Wells Fargo | Overweight |
| 2022-10-19 | 開始されました | Raymond James | Outperform |
| 2022-08-29 | 開始されました | BofA Securities | Buy |
| 2022-07-21 | 開始されました | JP Morgan | Overweight |
| 2021-10-28 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-10-02 | 開始されました | SVB Leerink | Outperform |
| 2020-07-21 | 開始されました | Needham | Buy |
| 2020-06-01 | 再開されました | Jefferies | Buy |
| 2020-03-25 | 開始されました | Wedbush | Outperform |
| 2020-01-08 | 開始されました | William Blair | Outperform |
| 2019-09-20 | 開始されました | Guggenheim | Buy |
| 2018-08-08 | 繰り返されました | Stifel | Buy |
| 2017-03-13 | 開始されました | Jefferies | Buy |
| 2016-10-21 | 開始されました | Stifel | Buy |
| 2016-09-26 | 開始されました | Guggenheim | Buy |
| 2016-04-14 | 繰り返されました | Jefferies | Buy |
| 2015-10-30 | 再開されました | Jefferies | Buy |
| 2014-12-02 | 開始されました | Canaccord Genuity | Buy |
すべてを表示
Xenon Pharmaceuticals Inc (XENE) 最新ニュース
Xenon Pharmaceuticals Inc (XENE) Q1 2025 Earnings Report Preview: What To Look For - GuruFocus
Xenon Pharmaceuticals (NASDAQ:XENE) Coverage Initiated at Chardan Capital - Defense World
Chardan Capital Initiates a Buy Rating on Xenon (XENE) - The Globe and Mail
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Purchased by Barclays PLC - Defense World
Ratio Analysis: Unpacking Xenon Pharmaceuticals Inc (XENE)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Chardan Capital Initiates Coverage of Xenon Pharmaceuticals (XENE) with Buy Recommendation - Nasdaq
XENE: Chardan Capital Initiates Coverage with Buy Rating and $55 Price Target | XENE Stock News - GuruFocus
Chardan Initiates Xenon Pharmaceuticals at Buy With $55 Price Target - marketscreener.com
XENE: Chardan Starts Coverage with Positive Outlook and $55 Target | XENE Stock News - GuruFocus
Raymond James Financial Inc. Makes New Investment in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Receives Outperform Rating from William Blair - Defense World
Xenon Pharmaceuticals to Announce Q1 2025 Financial Results - TipRanks
Xenon to Report Q1 2025 Financial Results on May 12, 2025 - The Manila Times
Xenon Q1 Earnings Preview: Key Updates Expected on Breakthrough Epilepsy Drug Azetukalner - Stock Titan
Wall Street Analysts See a 48.15% Upside in Xenon Pharmaceuticals (XENE): Can the Stock Really Move This High? - Yahoo Finance
(XENE) On The My Stocks Page - news.stocktradersdaily.com
Renaissance Technologies LLC Decreases Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Stock Rating Lowered by StockNews.com - Defense World
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | XENE Stock News - GuruFocus
Xenon Pharmaceuticals Announces Equity Inducement Grants to New Employees - TipRanks
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
This trade activity should not be overlooked: Xenon Pharmaceuticals Inc (XENE) - Sete News
Xenon Pharmaceuticals Expands Team with $3M Equity Package: 78,600 Options Granted to New Hires - Stock Titan
Upward Trajectory: Xenon Pharmaceuticals Inc (XENE) Posts a Slidee, Closing at 38.20 - DWinneX
Xenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Inc [XENE] MORTIMER IAN sells 22,468 Shares for $0.9 million - knoxdaily.com
Geode Capital Management LLC Purchases 720 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Envestnet Asset Management Inc. Sells 1,539 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Investor Network: Xenon Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Xenon Pharmaceuticals Inc (NASDAQ:XENE)’s 12-Month Price Target Currently Stands At 42 - Marketing Sentinel
StockNews.com Upgrades Xenon Pharmaceuticals (NASDAQ:XENE) to Hold - Defense World
Wells Fargo & Company MN Reduces Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Recommendation of “Buy” from Analysts - Defense World
Market Insights: Xenon Pharmaceuticals Inc (XENE)’s Notable Gain of 2.34, Closing at 37.59 - DWinneX
Xenon Pharmaceuticals Inc (XENE) is an excellent investment, but the stock is overvalued/undervalued right now - uspostnews.com
Xenon Pharmaceuticals (NASDAQ:XENE) Upgraded by StockNews.com to Hold Rating - Defense World
When (XENE) Moves Investors should Listen - news.stocktradersdaily.com
The Goldman Sachs Group Has Lowered Expectations for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price - Defense World
Xenon- A Later Stage Story (NASDAQ:XENE) - Seeking Alpha
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE) - Defense World
Q1 EPS Forecast for Xenon Pharmaceuticals Raised by Analyst - Defense World
Xenon Pharmaceuticals: Undervalued Stock with Promising Catalysts and Growth Potential - TipRanks
StockNews.com Downgrades Xenon Pharmaceuticals (NASDAQ:XENE) to Sell - Defense World
Sodium Channel Blockers Clinical Trial Pipeline Accelerates - GlobeNewswire
XENE stock touches 52-week low at $28.51 amid market shifts By Investing.com - Investing.com South Africa
XENE stock touches 52-week low at $28.51 amid market shifts - Investing.com
JPMorgan Chase & Co. Increases Stock Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Prudential Financial Inc. Acquires 24,956 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Raymond James Financial Inc. Buys New Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Looks Attractive Before Epilepsy Data (NASDAQ:XENE) - Seeking Alpha
Xenon Pharmaceuticals Inc (XENE) 財務データ
収益
当期純利益
現金流量
EPS
0.84%
0.15%
大文字化:
|
ボリューム (24 時間):